Generated Narrative: ValueSet R3-v2-0292-for-R5 This value set expansion contains 124 concepts. System Version Code Display http://hl7.org/fhir/v2/0292 2.8.2 01 DTP http://hl7.org/fhir/v2/0292 2.8.2 02 OPV http://hl7.org/fhir/v2/0292 2.8.2 03 MMR http://hl7.org/fhir/v2/0292 2.8.2 04 M/R http://hl7.org/fhir/v2/0292 2.8.2 05 measles http://hl7.org/fhir/v2/0292 2.8.2 06 rubella http://hl7.org/fhir/v2/0292 2.8.2 07 mumps http://hl7.org/fhir/v2/0292 2.8.2 08 Hep B, adolescent or pediatric http://hl7.org/fhir/v2/0292 2.8.2 09 Td (adult) http://hl7.org/fhir/v2/0292 2.8.2 10 IPV http://hl7.org/fhir/v2/0292 2.8.2 100 pneumococcal conjugate http://hl7.org/fhir/v2/0292 2.8.2 101 typhoid, ViCPs http://hl7.org/fhir/v2/0292 2.8.2 102 DTP-Hib-Hep B http://hl7.org/fhir/v2/0292 2.8.2 103 meningococcal C conjugate http://hl7.org/fhir/v2/0292 2.8.2 104 Hep A-Hep B http://hl7.org/fhir/v2/0292 2.8.2 105 vaccinia (smallpox) diluted http://hl7.org/fhir/v2/0292 2.8.2 106 DTaP, 5 pertussis antigens6 http://hl7.org/fhir/v2/0292 2.8.2 107 DTaP, NOS http://hl7.org/fhir/v2/0292 2.8.2 108 meningococcal, NOS http://hl7.org/fhir/v2/0292 2.8.2 109 pneumococcal, NOS http://hl7.org/fhir/v2/0292 2.8.2 11 pertussis http://hl7.org/fhir/v2/0292 2.8.2 110 DTaP-Hep B-IPV http://hl7.org/fhir/v2/0292 2.8.2 111 influenza, live, intranasal http://hl7.org/fhir/v2/0292 2.8.2 112 tetanus toxoid, NOS http://hl7.org/fhir/v2/0292 2.8.2 113 Td (adult) http://hl7.org/fhir/v2/0292 2.8.2 114 meningococcal A,C,Y,W-135 diphtheria conjugate http://hl7.org/fhir/v2/0292 2.8.2 115 Tdap http://hl7.org/fhir/v2/0292 2.8.2 116 rotavirus, pentavalent http://hl7.org/fhir/v2/0292 2.8.2 117 VZIG (IND) http://hl7.org/fhir/v2/0292 2.8.2 118 HPV, bivalent http://hl7.org/fhir/v2/0292 2.8.2 119 rotavirus, monovalent http://hl7.org/fhir/v2/0292 2.8.2 12 diphtheria antitoxin http://hl7.org/fhir/v2/0292 2.8.2 120 DTaP-Hib-IPV http://hl7.org/fhir/v2/0292 2.8.2 121 zoster http://hl7.org/fhir/v2/0292 2.8.2 122 rotavirus, NOS1 http://hl7.org/fhir/v2/0292 2.8.2 13 TIG http://hl7.org/fhir/v2/0292 2.8.2 14 IG, NOS http://hl7.org/fhir/v2/0292 2.8.2 15 influenza, split (incl. purified surface antigen) http://hl7.org/fhir/v2/0292 2.8.2 16 influenza, whole http://hl7.org/fhir/v2/0292 2.8.2 17 Hib, NOS http://hl7.org/fhir/v2/0292 2.8.2 18 rabies, intramuscular injection http://hl7.org/fhir/v2/0292 2.8.2 19 BCG http://hl7.org/fhir/v2/0292 2.8.2 20 DTaP http://hl7.org/fhir/v2/0292 2.8.2 21 varicella http://hl7.org/fhir/v2/0292 2.8.2 22 DTP-Hib http://hl7.org/fhir/v2/0292 2.8.2 23 plague http://hl7.org/fhir/v2/0292 2.8.2 24 anthrax http://hl7.org/fhir/v2/0292 2.8.2 25 typhoid, oral http://hl7.org/fhir/v2/0292 2.8.2 26 cholera http://hl7.org/fhir/v2/0292 2.8.2 27 botulinum antitoxin http://hl7.org/fhir/v2/0292 2.8.2 28 DT (pediatric) http://hl7.org/fhir/v2/0292 2.8.2 29 CMVIG http://hl7.org/fhir/v2/0292 2.8.2 30 HBIG http://hl7.org/fhir/v2/0292 2.8.2 31 Hep A, pediatric, NOS http://hl7.org/fhir/v2/0292 2.8.2 32 meningococcal http://hl7.org/fhir/v2/0292 2.8.2 33 pneumococcal http://hl7.org/fhir/v2/0292 2.8.2 34 RIG http://hl7.org/fhir/v2/0292 2.8.2 35 tetanus toxoid http://hl7.org/fhir/v2/0292 2.8.2 36 VZIG http://hl7.org/fhir/v2/0292 2.8.2 37 yellow fever http://hl7.org/fhir/v2/0292 2.8.2 38 rubella/mumps http://hl7.org/fhir/v2/0292 2.8.2 39 Japanese encephalitis http://hl7.org/fhir/v2/0292 2.8.2 40 rabies, intradermal injection http://hl7.org/fhir/v2/0292 2.8.2 41 typhoid, parenteral http://hl7.org/fhir/v2/0292 2.8.2 42 Hep B, adolescent/high risk infant2 http://hl7.org/fhir/v2/0292 2.8.2 43 Hep B, adult4 http://hl7.org/fhir/v2/0292 2.8.2 44 Hep B, dialysis http://hl7.org/fhir/v2/0292 2.8.2 45 Hep B, NOS http://hl7.org/fhir/v2/0292 2.8.2 46 Hib (PRP-D) http://hl7.org/fhir/v2/0292 2.8.2 47 Hib (HbOC) http://hl7.org/fhir/v2/0292 2.8.2 48 Hib (PRP-T) http://hl7.org/fhir/v2/0292 2.8.2 49 Hib (PRP-OMP) http://hl7.org/fhir/v2/0292 2.8.2 50 DTaP-Hib http://hl7.org/fhir/v2/0292 2.8.2 51 Hib-Hep B http://hl7.org/fhir/v2/0292 2.8.2 52 Hep A, adult http://hl7.org/fhir/v2/0292 2.8.2 53 typhoid, parenteral, AKD (U.S. military) http://hl7.org/fhir/v2/0292 2.8.2 54 adenovirus, type 4 http://hl7.org/fhir/v2/0292 2.8.2 55 adenovirus, type 7 http://hl7.org/fhir/v2/0292 2.8.2 56 dengue fever http://hl7.org/fhir/v2/0292 2.8.2 57 hantavirus http://hl7.org/fhir/v2/0292 2.8.2 58 Hep C http://hl7.org/fhir/v2/0292 2.8.2 59 Hep E http://hl7.org/fhir/v2/0292 2.8.2 60 herpes simplex 2 http://hl7.org/fhir/v2/0292 2.8.2 61 HIV http://hl7.org/fhir/v2/0292 2.8.2 62 HPV, quadrivalent http://hl7.org/fhir/v2/0292 2.8.2 63 Junin virus http://hl7.org/fhir/v2/0292 2.8.2 64 leishmaniasis http://hl7.org/fhir/v2/0292 2.8.2 65 leprosy http://hl7.org/fhir/v2/0292 2.8.2 66 Lyme disease http://hl7.org/fhir/v2/0292 2.8.2 67 malaria http://hl7.org/fhir/v2/0292 2.8.2 68 melanoma http://hl7.org/fhir/v2/0292 2.8.2 69 parainfluenza-3 http://hl7.org/fhir/v2/0292 2.8.2 70 Q fever http://hl7.org/fhir/v2/0292 2.8.2 71 RSV-IGIV http://hl7.org/fhir/v2/0292 2.8.2 72 rheumatic fever http://hl7.org/fhir/v2/0292 2.8.2 73 Rift Valley fever http://hl7.org/fhir/v2/0292 2.8.2 74 rotavirus, tetravalent http://hl7.org/fhir/v2/0292 2.8.2 75 vaccinia (smallpox) http://hl7.org/fhir/v2/0292 2.8.2 76 Staphylococcus bacterio lysate http://hl7.org/fhir/v2/0292 2.8.2 77 tick-borne encephalitis http://hl7.org/fhir/v2/0292 2.8.2 78 tularemia vaccine http://hl7.org/fhir/v2/0292 2.8.2 79 vaccinia immune globulin http://hl7.org/fhir/v2/0292 2.8.2 80 VEE, live http://hl7.org/fhir/v2/0292 2.8.2 81 VEE, inactivated http://hl7.org/fhir/v2/0292 2.8.2 82 adenovirus, NOS1 http://hl7.org/fhir/v2/0292 2.8.2 83 Hep A, ped/adol, 2 dose http://hl7.org/fhir/v2/0292 2.8.2 84 Hep A, ped/adol, 3 dose http://hl7.org/fhir/v2/0292 2.8.2 85 Hep A, NOS http://hl7.org/fhir/v2/0292 2.8.2 86 IG http://hl7.org/fhir/v2/0292 2.8.2 87 IGIV http://hl7.org/fhir/v2/0292 2.8.2 88 influenza, NOS http://hl7.org/fhir/v2/0292 2.8.2 89 polio, NOS http://hl7.org/fhir/v2/0292 2.8.2 90 rabies, NOS http://hl7.org/fhir/v2/0292 2.8.2 91 typhoid, NOS http://hl7.org/fhir/v2/0292 2.8.2 92 VEE, NOS http://hl7.org/fhir/v2/0292 2.8.2 93 RSV-MAb http://hl7.org/fhir/v2/0292 2.8.2 94 MMRV http://hl7.org/fhir/v2/0292 2.8.2 95 TST-OT tine test http://hl7.org/fhir/v2/0292 2.8.2 96 TST-PPD intradermal http://hl7.org/fhir/v2/0292 2.8.2 97 TST-PPD tine test http://hl7.org/fhir/v2/0292 2.8.2 98 TST, NOS http://hl7.org/fhir/v2/0292 2.8.2 99 RESERVED - do not use3 http://hl7.org/fhir/v2/0292 2.8.2 998 no vaccine administered5 http://hl7.org/fhir/v2/0292 2.8.2 999 unknown
Cross-version ValueSet STU3.v2 Vaccines Administered (code = CVX) (parenteral, un for use in FHIR R5
This cross-version ValueSet represents content from `http://hl7.org/fhir/ValueSet/v2-0292|2.8.2` for use in FHIR R5.
This value set is part of the cross-version definitions generated to enable use of the value set `http://hl7.org/fhir/ValueSet/v2-0292|2.8.2` as defined in FHIR STU3 in FHIR R5. The source value set is bound to the following FHIR STU3 elements: * Note that all concepts are included in this cross-version definition because no concepts have compatible representations Following are the generation technical comments: FHIR ValueSet `http://hl7.org/fhir/ValueSet/v2-0292|2.8.2`, defined in FHIR STU3 does not have any mapping to FHIR R5
meningococcal A,C,Y,W-135 diphtheria conjugate
influenza, split (incl. purified surface antigen)
typhoid, parenteral, AKD (U.S. military)